These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 25141273)
1. Risk of bias in trial-based economic evaluations: identification of sources and bias-reducing strategies. Evers SM; Hiligsmann M; Adarkwah CC Psychol Health; 2015 Jan; 30(1):52-71. PubMed ID: 25141273 [TBL] [Abstract][Full Text] [Related]
2. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Adarkwah CC; van Gils PF; Hiligsmann M; Evers SM Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):513-23. PubMed ID: 26588001 [TBL] [Abstract][Full Text] [Related]
3. Economic Impact of Third-Wave Cognitive Behavioral Therapies: A Systematic Review and Quality Assessment of Economic Evaluations in Randomized Controlled Trials. Feliu-Soler A; Cebolla A; McCracken LM; D'Amico F; Knapp M; López-Montoyo A; García-Campayo J; Soler J; Baños RM; Pérez-Aranda A; Andrés-Rodriguez L; Rubio-Valera M; Luciano JV Behav Ther; 2018 Jan; 49(1):124-147. PubMed ID: 29405918 [TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations. Dakin H; Gray A Stat Med; 2017 Aug; 36(18):2814-2830. PubMed ID: 28470760 [TBL] [Abstract][Full Text] [Related]
5. Reducing the risk of bias in health behaviour change trials: improving trial design, reporting or bias assessment criteria? A review and case study. de Bruin M; McCambridge J; Prins JM Psychol Health; 2015 Jan; 30(1):8-34. PubMed ID: 25112431 [TBL] [Abstract][Full Text] [Related]
6. Are current standards of reporting quality for clinical trials sufficient in addressing important sources of bias? Mills EJ; Ayers D; Chou R; Thorlund K Contemp Clin Trials; 2015 Nov; 45(Pt A):2-7. PubMed ID: 26232560 [TBL] [Abstract][Full Text] [Related]
7. Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology. Gaultney JG; Redekop WK; Sonneveld P; Uyl-de Groot CA Eur J Cancer; 2011 Jul; 47(10):1458-67. PubMed ID: 21561761 [TBL] [Abstract][Full Text] [Related]
8. The relevance of searching for effects under a clinical-trial lamppost: a key issue. Rittenhouse BE Med Decis Making; 1995; 15(4):348-57. PubMed ID: 8544678 [TBL] [Abstract][Full Text] [Related]
9. Factors to consider when designing phase III clinical trials involving economic evaluations. van Enckevort PJ; TenVergert EM; Kingma J; Koëter GH; Rutten FF Percept Mot Skills; 1999 Dec; 89(3 Pt 2):1059-72. PubMed ID: 10710753 [TBL] [Abstract][Full Text] [Related]